Abstract 804
Background
A decrease lymphocyte to monocyte ratio (LMR) has been reported to be related with worsen prognosis for certain hematologic and solid malignancies. Also pretreatment LMR is associated with the prognosis of patients with breast cancer. However, relationship between treatment-related low LMR and prognostic impact has not well been investigated in breast cancer. The purpose of this study is to evaluate the relationship between radiotherapy (RT)-induced low LMR and recurrence in patients with breast cancer.
Methods
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Results
We retrospectively reviewed 1,735 patients with stage I to III breast cancer treated with breast conserving surgery (BCS) and adjuvant RT at Gangnam Severance Hospital and Severance Hospital from January 2006 to 2016 December. The values of LMR were calculated at baseline (A1), before the first RT administration (A2) and before the last RT administration (A3). The reference point of RT-induced low LMR was defined as ≤ 2.6 used in other studies. The recurrence-free survival (RFS) was compared according to RT-induced LMR.
Conclusions
We demonstrated that RT-induced low LMR is a poor prognostic factor for patients with BCS and adjuvant RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract
2444 - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in Oesophageal adenocarcinoma
Presenter: Emma Ococks
Session: Poster Display session 2
Resources:
Abstract